Kinetic analysis of platelet monoamine oxidase in chronic schizophrenia

Alan Breier, Robert J. Hitzemann, Jack Hirschowitz, David L. Garver

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Km and Vmax values for platelet monoamine oxidase (MAO) were determined in 16 chronic schizophrenics and 18 controls utilizing three substrates, tyramine (TYR), benzylamine (BZ), and phenylethylamine (PEA). In the chronic schizophrenics decreased Km and Vmax values were found for TYR and BZ but not PEA. When prior neuroleptic drug exposure was considered, a trend toward lower kinetic parameters was found in schizophrenics with a history of prior neuroleptic usage. We conclude that platelet MAO activity is, in chronic schizophrenics, both quantitatively reduced and qualitatively different from control enzyme. We suggest that the measurement of Km in addition to the measurement of Vmax may be a useful biological marker for chronic schizophrenia providing that the appropriate substrates are employed.

Original languageEnglish (US)
Pages (from-to)1947-1951
Number of pages5
JournalLife Sciences
Volume28
Issue number17
DOIs
StatePublished - Apr 27 1981
Externally publishedYes

ASJC Scopus subject areas

  • General Pharmacology, Toxicology and Pharmaceutics
  • General Biochemistry, Genetics and Molecular Biology

Fingerprint

Dive into the research topics of 'Kinetic analysis of platelet monoamine oxidase in chronic schizophrenia'. Together they form a unique fingerprint.

Cite this